-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Accendra Health, Lowers Price Target to $1.5

Benzinga·08/13/2026 21:11:57
语音播报
UBS analyst Kevin Caliendo maintains Accendra Health (NYSE:ACH) with a Neutral and lowers the price target from $4.5 to $1.5.